Repare Therapeutics, Inc.

As of August 8, 2025, Repare Therapeutics, Inc. has deteriorated from a risky to a non-qualifying valuation grade due to significant overvaluation and poor financial metrics, including a Price to Book Value of 0.50 and a negative return on equity of -98.52%, alongside a troubling stock performance with a one-year return of -46.84% compared to the S&P 500's 17.14%.

As of March 1, 2022, Repare Therapeutics, Inc. is considered overvalued and classified as "risky" due to negative financial metrics, including a -98.52% Return on Equity and poor performance compared to peers, with a 60.06% decline in stock value over the past year.

As of May 5, 2025, Repare Therapeutics, Inc. shows a mildly bearish trend due to daily moving averages and weekly RSI, despite some mixed signals from MACD and Bollinger Bands.

As of March 2022, the management team of Repare Therapeutics, Inc. includes Mr. Lloyd Segal (CEO), Mr. Jerel Davis (Chairman), and several independent directors, including Dr. David Bonita, Mr. Todd Foley, Dr. Samarth Kulkarni, Dr. Briggs Morrison, and Mr. Kevin Raidy. This team provides governance and strategic direction for the company.

Repare Therapeutics, Inc. is a precision oncology company focused on targeting tumor vulnerabilities in genetically defined patient populations. It has a market cap of approximately $60.91 million and reported a net profit loss of $30 million as of March 2025.

As of Jun 18, Repare Therapeutics, Inc. has a market capitalization of 60.91 million, with net sales of 1.07 million and a net profit of -127.89 million over the last four quarters. The company's shareholder's funds are 151.13 million, and total assets are 176.51 million.